Pediatric Mental Health, Treatment, and COVID-19

Video

An expert discusses trends in pediatric mental health and receipt of treatment.

A recent study published by the National Center for Health Statistics found disparities among US children in the receipt of treatment for mental health disorders.

According to the data, older children (12-17 years), boys, non-Hispanic white children, and those from less urban areas had a greater likelihood of receiving any treatment—which range from medication to counseling by a professional.

In an interview with HCPLive®, Benjamin Zablotsky, PhD, Health Statistician, Centers for Disease Control and Prevention (CDC), explained that capturing receipt of treatment offers a better understanding of how children receive care throughout the country.

“Ideally, we want to use a dataset that is timely and nationally representative,” he said.

In reference to the impact of the coronavirus disease 2019 (COVID-19) pandemic, Zablotsky underscored the importance of continuing to collect similar data among children. Since the pandemic has upended daily life, especially in the healthcare sector, it is especially necessary that mental health treatment behaviors from 2020 can be compared with the previous year.

Zablotsky also explained that the survey from this year now includes questions about delaying care because of the pandemic.

“Once that data is available, it would be curious to see if in fact there were children in need of services who couldn’t get them due to COVID,” he noted.

He also suggested that the rise of telemedicine might allow a standard for mental health therapy to exist. Although this question falls outside the purview of the CDC’s upcoming report, he still stressed that it would still be useful to know.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
© 2024 MJH Life Sciences

All rights reserved.